Targets › SLC22A6
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Neurology, Psychiatry; next expected readout May 2027.
Secondary active transporter that functions as a Na(+)-independent organic anion (OA)/dicarboxylate antiporter where the uptake of one molecule of OA into the cell is coupled with an efflux of one molecule of intracellular dicarboxylate such as 2-oxoglutarate or glutarate. Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of…. (UniProt, Q4U2R8)
Open in Phaseline: the race on SLC22A6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Miami | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 3 | Infertility, Male | May 2027 |
| Fondation Ophtalmologique Adolphe de Rothschild | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 2 | Focal Epilepsy | Sep 2029 |
| Brown University | Probenecid Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor | SLC22A6, SLC22A8, SLC22A11 | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2030 |
Infertility, Male (1) Alcohol Use Disorder (AUD) (1) Focal Epilepsy (1)
small molecule (3)
University of Miami (1) Brown University (1) Fondation Ophtalmologique Adolphe de Rothschild (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.